Details for Patent: 11,957,674
Which drugs does patent 11,957,674 protect, and when does it expire?
Patent 11,957,674 protects PALSONIFY and is included in one NDA.
This patent has thirty-two patent family members in twenty-seven countries.
Summary for Patent: 11,957,674
| Title: | Formulations of a somatostatin modulator | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Crinetics Pharmaceuticals Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US17/584,225 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 11,957,674: Paltusotine Claims, Exclusivity, Formulation Scope, and Generic RiskUS Patent No. 11,957,674 protects oral administration of paltusotine, an oral growth hormone receptor 2 agonist, for suppressing growth hormone and related hormones. The patent is directed primarily to dosing conditions, endocrine indications, dose range, and amorphous solid-dispersion formulations. The commercial risk is concentrated in claims 1, 2, 4-6 and 15 for ordinary oral use, and in claims 7-14 for specific spray-dried formulations containing HPMCAS or PVP/VA polymers. A generic or follow-on product would need to avoid the claimed compound, the claimed empty-stomach dosing condition, the specified formulation architecture, or the covered endocrine treatment indications. What drug does US Patent 11,957,674 protect?The claimed active pharmaceutical ingredient is paltusotine, identified in the patent by its chemical name: 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile. The claims also cover pharmaceutically acceptable salts and, in specified claims, solvates. The hydrochloride salt is the principal form described in the claims.
The patent claims treatment methods rather than a new molecular entity. Its commercial value therefore depends on use of paltusotine in the covered endocrine indications and on whether the marketed product uses the claimed formulation and dosing instructions. What does independent claim 1 cover?Claim 1 requires all of the following elements:
The claim is broad in its biological endpoint. It does not require acromegaly, neuroendocrine tumors, once-daily dosing, a specific tablet composition, a particular dose, or a specific polymer. That breadth creates two important consequences. First, a product can potentially fall within claim 1 even if its label does not expressly identify every hormone endpoint, provided the claimed treatment method is practiced and the product is used under the claimed conditions. Second, claim 1 is narrower than a general composition or compound claim. A product containing paltusotine but labeled for administration with food, or without a 30-minute pre-meal instruction, would present a different infringement analysis. Actual prescribing and patient use could still matter for induced-infringement theories. Which claims cover acromegaly and neuroendocrine tumors?Claims 2 and 3 add the disease limitation:
Claim 2 is commercially more important if the approved product is indicated for acromegaly. Claim 3 is relevant to development programs involving hormone-secreting neuroendocrine tumors. These claims are method-of-use claims. They do not require a particular tumor subtype, prior treatment, biomarker, baseline hormone level, or treatment duration. Their scope may therefore extend across multiple patient populations, subject to the ordinary rules governing claim construction and written-description support. What dose and dosing schedule are protected?Claims 4, 5, 6 and 15 create a dose-and-administration cluster.
Claim 6 is the most commercially specific dosing claim. It combines active ingredient, frequency, water administration and pre-meal timing. Claim 15 is broader than claim 6 because it does not repeat the fasting or water limitations. The use of "equivalent to" in claim 4 is intended to capture non-hydrochloride forms or different salt or solvate forms measured against the stated amount of the monohydrochloride. Generic developers would need to assess whether their proposed strength, salt form and label fall within that equivalence limitation. A 20 mg, 40 mg or 60 mg tablet administered once daily before breakfast would likely be the highest-risk design if it contains paltusotine and is labeled for acromegaly. What formulations are protected by US 11,957,674?Claims 7-14 protect formulations built around a spray-dried dispersion, or SDD. The formulation claims require a defined relationship between the active ingredient, polymer matrix and excipients. HPMCAS and PVP/VA polymer claimsThe two principal polymer alternatives are:
Claims 7 and 8 cover either polymer system. Claims 9 and 10 focus on HPMCAS. Claims 11-14 focus on PVP/VA. The claimed active-to-polymer ratio is approximately 15/85 to 35/65. This is a material limitation. A formulation containing paltusotine with a polymer ratio outside that range may avoid the literal ratio limitation, although the formulation could still raise equivalence issues depending on the patent’s construction and prosecution history.
Excipients covered by claims 7-14The claims identify excipient classes and, in claim 14, specific materials:
The formulation claims are cumulative. A product must satisfy the parent method claim and the additional composition limitations. A tablet using paltusotine but a conventional crystalline formulation, without the claimed SDD structure, would not literally satisfy claims 7-14. How strong is the patent estate?The patent estate is strongest where the commercial product matches the patent’s dosing instructions and formulation architecture.
The principal vulnerability is that many claims are method claims tied to observable clinical instructions. That makes infringement easier to evaluate from product labeling, prescribing information, clinical protocols and marketing materials. The formulation claims are narrower but can provide a second layer of protection if the commercial tablet uses one of the claimed SDD systems. The main validity pressure points would likely involve written description, enablement, obviousness of the dosing regimen, obviousness of the formulation composition, and whether the claimed fasting instruction produces a patentable clinical or pharmacokinetic distinction over prior art. When does US Patent 11,957,674 expire?The exact expiration date depends on the patent’s earliest effective nonprovisional filing date, patent-term adjustment, any terminal disclaimer and any patent-term extension. A US utility patent normally receives a term of 20 years from the earliest effective nonprovisional filing date, subject to those adjustments (35 U.S.C. § 154). The patent’s issue date was May 7, 2024. The issue date does not control expiration. For commercial analysis, the relevant date is the patent’s adjusted expiration date shown in USPTO records and, if listed, FDA Orange Book records. The patent should be treated as a late-2030s exclusivity asset based on the underlying paltusotine development timeline, but an exact expiration date should not be inferred solely from the patent number or issue date. What is the FDA and Orange Book status?Paltusotine is an orally administered small-molecule SSTR2 agonist developed by Crinetics Pharmaceuticals for acromegaly. The principal FDA pathway is an NDA, not a biologics license application. The product is therefore subject to generic-drug competition under the Hatch-Waxman framework. A future abbreviated new drug application could use an ANDA pathway if the reference product and proposed generic satisfy the applicable requirements.
A method-of-use patent may be listed in the Orange Book if it claims an approved use and meets FDA listing requirements. A generic applicant could issue a Paragraph IV certification against a listed patent, asserting that the patent is invalid, unenforceable or not infringed. The patent holder could then file an infringement action within the statutory period, potentially triggering a 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii). Which companies are challenging paltusotine exclusivity?No public Paragraph IV litigation or settlement involving US 11,957,674 is established by the claim information alone. The likely challengers would be generic drug companies with experience in complex oral formulations and ANDA litigation, particularly companies capable of developing amorphous solid dispersions and characterizing polymer-based dissolution systems. Potential competitive categories include:
The principal design-around options would be:
The fourth option is difficult if the approved product’s clinical performance depends on fasting administration. A generic applicant generally must demonstrate bioequivalence to the reference product, which may constrain meaningful changes to food instructions. What other patents are likely to matter?US 11,957,674 should be analyzed as one part of a broader paltusotine portfolio. Relevant patent families may cover:
A freedom-to-operate review should compare each family by earliest priority date, claim type, jurisdiction, terminal disclaimer, continuation status, PTA, PTE eligibility and Orange Book listing. A single unexpired compound or formulation patent could block launch even if US 11,957,674 is invalidated. How does paltusotine compare with competing acromegaly drugs?
Paltusotine’s competitive differentiation is oral administration without injections. Its patent exposure is therefore tied to both the active ingredient and the oral delivery technology needed to achieve adequate exposure. What revenue exposure does this patent create?The patent directly protects revenue from paltusotine tablets used for acromegaly and potentially neuroendocrine tumors. The most valuable claims are likely claims 1, 2, 4, 5, 6 and 15 because they track ordinary product use rather than a narrow manufacturing configuration. Revenue exposure depends on:
The SDD claims provide meaningful secondary protection. They may delay competition even if a generic avoids a narrow method claim, particularly if the reference product’s bioavailability depends on the claimed polymer system. What patent litigation or settlement agreements affect the patent?The supplied claim set does not identify litigation, a Paragraph IV notice, a settlement agreement or a license. A complete litigation conclusion requires review of PACER, district-court dockets, the Federal Circuit docket, USPTO prosecution records and FDA Orange Book updates. No license is apparent from the patent claim language. Crinetics has been the principal developer of paltusotine, and the commercial risk analysis should distinguish an internal product portfolio from third-party licensing rights. Key Takeaways
FAQsCan a generic avoid US 11,957,674 by administering paltusotine with food?Potentially, if the product is genuinely labeled and used with food and does not satisfy the claim’s empty-stomach limitation. That strategy may be constrained by bioequivalence requirements and the reference product’s approved food-effect instructions. Does the patent cover every paltusotine tablet?No. The broadest claim requires a covered oral treatment method and pre-meal administration. Claims 7-14 add specific SDD and polymer limitations. A paltusotine product using a different formulation may avoid the formulation claims but remain exposed to method claims and other patent families. Is paltusotine subject to biosimilar competition?No. Paltusotine is a small molecule. The relevant competition model is generic-drug competition through an ANDA, not biosimilar substitution under the Public Health Service Act. Can a generic use a different polymer from HPMCAS or PVP/VA?A different polymer may avoid the literal polymer limitations in claims 7-14. It would not automatically avoid claim 1 or other patents covering the compound, dose, indication, solid form or manufacturing process. Is claim 6 broader than claim 15?No. Claim 6 adds once-daily administration, a glass of water and the empty-stomach, 30-minute pre-meal condition. Claim 15 focuses on the 20-60 mg hydrochloride dose. Each claim has different limitations, and claim 6 is narrower in express scope. References
More… ↓ |
Drugs Protected by US Patent 11,957,674
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-001 | Sep 25, 2025 | RX | Yes | No | 11,957,674 | ⤷ Start Trial | TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION | ⤷ Start Trial | ||||
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-002 | Sep 25, 2025 | RX | Yes | Yes | 11,957,674 | ⤷ Start Trial | TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,957,674
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 123453 | ⤷ Start Trial | |||
| Australia | 2021341936 | ⤷ Start Trial | |||
| Canada | 3191084 | ⤷ Start Trial | |||
| Chile | 2023000627 | ⤷ Start Trial | |||
| China | 116456968 | ⤷ Start Trial | |||
| China | 121943816 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
